Live Lighter Pakistan: Obesity Care Initiative

The Live Lighter Pakistan program by Novo Nordisk marks a new step in tackling obesity in the country. The Karachi launch at Mohatta Palace brought together health leaders, policymakers, and media to discuss better care options for patients living with obesity. The Islamabad press briefing outlined a plan to expand obesity care across Pakistan while complying with local rules.

At the event, Maja Mortensen, the Danish Ambassador to Pakistan, stressed that strong partnerships are key to improving health outcomes. She added that addressing obesity requires collaboration between government, industry, and communities, not just individual effort.

Tasnim Ahsan, Dean of Medicell Institute of Diabetes Endocrinology & Metabolism, spoke about patient journeys and the need for guided weight management through medical care. Rashed Rafique Butt, Novo Nordisk Pakistan’s representative, underscored the company’s long-term commitment and its science-led approach to obesity treatment.

Industry and health experts noted obesity links to more than 200 conditions, reinforcing the need for action. The campaign highlighted Wegovy, the semaglutide 2.4 mg therapy, which has FDA and EMA approvals. Novo Nordisk aims to broaden access to therapies in Pakistan within local regulatory frameworks and country-specific programs.

The Live Lighter initiative signals a shift toward science-based care. While lifestyle changes remain important, medications under professional supervision can play a vital role for many patients. The program calls for national health strategies that blend medical therapies with lifestyle support and encourage proactive conversations between patients and clinicians.

In summary, Live Lighter Pakistan reflects Novo Nordisk’s long history in diabetes care—over 100 years—and more than three decades of obesity research. The company emphasizes responsible access and ongoing collaboration with Pakistani health partners to improve outcomes for the population.

The event also highlighted the practical steps needed to bring Wegovy and other therapies to clinics in Pakistan, including patient selection, monitoring for side effects, and affordability programs. Attendees learned how the dosing schedule of semaglutide 2.4 mg supports sustained weight loss when combined with diet and activity changes.

By combining public health messaging with innovative medicines, Live Lighter aims to reduce obesity-related burdens such as diabetes, cardiovascular disease, and liver conditions. The collaboration with local health authorities seeks to deliver care closer to families in Karachi, Lahore, Islamabad, and beyond.